T. I. Ionova1, K. V. Lepik2, N. B. Mikhailova2, T. P. Nikitina1, N.M.Porfirieva1, L. V. Fedorova2, B. V. Afanasiev2
Quality of life in patients with relapsed/refractory Hodgkin lymphoma receiving nivolumab in real clinical practice
1MULTINATIONAL CENTER FOR QUALITY OF LIFE RESEARCH, SAINT-PETERSBURG
2RAISA GORBACHEVA MEMORIAL RESEARCH INSTITUTE OF CHILDREN ONCOLOGY, HEMATOLOGY AND TRANSPLANTATION, I. P. PAVLOV FIRST SAINT-PETERSBURG STATE MEDICAL UNIVERSITY, SAINT-PETERSBURG
Comprehensive evaluation of treatment outcomes in relapsed/refractory classical Hodgkin lymphoma (cHL) is worthwhile. The aim of the present study is to evaluate quality of life (QoL) and symptoms in patients with relapsed/refractory classical Hodgkin lymphoma receiving nivolumab in a real clinical setting. The total of 100 patients with the confirmed relapsed/refractory classical Hodgkin lymphoma were enrolled in the study (the median age 33 years, 52 % — men). All the patients filled out questionnaires for QoL assessment (RAND SF-36, EQ-5D) and symptoms assessment (CSP Lym) before nivolumab treatment start, in 3, 6, 9 and 12 months after an initiation of treatment. Nivolumab therapy was accompanied by remarkable QoL improvement and decrease of symptoms during 12 months of treatment with nivolumab (GEE, p<0,05). The proportion of patients with a significant QoL impairment decreased during 12 months of therapy with nivolumab as compared with baseline (p < 0,05). During nivolumab treatment a decrease in the severity of the vast majority of estimated symptoms was observed (p<0,05). The results obtained demonstrate benefits of nivolumab treatment from patients’ perspective. These data confirm the importance of patient-reported outcomes when assessing the effects of treatment in patients with relapsed/refractory classical Hodgkin lymphoma.